Eli Lilly has announced results from the TRIUMPH-1 Phase 3 clinical trial of retatrutide, a once-weekly injectable triple hormone receptor agonist targeting the GLP-1, GIP, and glucagon receptors simultaneously. The findings, announced by Eli Lilly, represent what may be the most significant weight loss data ever reported in a randomized controlled trial of a pharmacological agent — and they are drawing intense attention from both the clinical and patient communities.
Retatrutide — commonly referred to as reta in patient communities — works differently from earlier-generation medications. Rather than activating one or two metabolic pathways, it acts simultaneously on three: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This triple receptor engagement, sometimes called triple G in patient shorthand, is the mechanistic basis for the outsized efficacy now being observed across Phase 2 and Phase 3 studies.
TRIUMPH-1 enrolled adults with obesity or overweight with at least one weight-related comorbidity — consistent with the enrollment criteria used in earlier Phase 2 research — and evaluated retatrutide over 80 weeks. The 12mg once-weekly dose served as the primary efficacy arm. Across all prespecified endpoints, the results were striking.
Participants receiving retatrutide 12mg lost an average of 70.3 pounds, representing 28.3% of total body weight over the 80-week trial period, according to Eli Lilly's announcement. For context, a person starting at 250 pounds would, on average, reach approximately 179 pounds — a transformation that would historically have required surgical intervention to achieve reliably.
Eli Lilly also noted that some participants lost up to approximately 85 pounds, or close to 30% of their starting body weight. These numbers are consistent with — and in some respects exceed — the findings already observed in the TRIUMPH-4 Phase 3 trial, which reported a mean weight loss of 28.7% at the 12mg dose over 68 weeks. Taken together, the TRIUMPH-4 and TRIUMPH-1 data present a coherent picture: retatrutide 12mg reliably delivers weight loss in the high-20s percentage range in adults without type 2 diabetes.
For patients who struggle with food noise — the persistent, intrusive preoccupation with food that drives overconsumption even in the absence of true hunger — the triple agonist mechanism of retatrutide appears to address appetite regulation through multiple overlapping pathways. The glucagon receptor component also enhances energy expenditure, which may partly explain why retatrutide's efficacy extends beyond what GLP-1 receptor agonism alone produces.
For decades, bariatric surgery — particularly Roux-en-Y gastric bypass and sleeve gastrectomy — represented the only reliable path to 20–30% total body weight loss. That benchmark is now being approached, and in some cases met, by pharmacological therapy. The comparison below illustrates where retatrutide stands relative to other major interventions.
| Intervention | Trial / Source | Duration | Mean % Weight Loss |
|---|---|---|---|
| Semaglutide 2.4mg (Wegovy) | STEP-1 | 68 weeks | ~14.9% |
| Tirzepatide 15mg (Zepbound) | SURMOUNT-1 | 72 weeks | ~20.9% |
| Retatrutide 12mg | TRIUMPH-4 (Phase 3) | 68 weeks | ~28.7% |
| Retatrutide 12mg | TRIUMPH-1 (Phase 3) | 80 weeks | ~28.3% |
| Sleeve Gastrectomy | Published surgical literature | 12–24 months | ~25–30% |
| Roux-en-Y Gastric Bypass | Published surgical literature | 12–24 months | ~30–35% |
Retatrutide is not a surgical procedure, carries no requirement for general anesthesia, and involves no permanent anatomical alteration. The weight loss it produces, however, now occupies the same quantitative range as sleeve gastrectomy — a fact that represents a meaningful shift in what non-surgical obesity medicine can offer.
One of the most clinically meaningful findings from TRIUMPH-1 is the proportion of participants achieving deep, sustained weight loss. According to Eli Lilly's announcement, 45.3% of participants receiving retatrutide 12mg achieved ≥30% total body weight loss — a threshold that has long been associated primarily with bariatric surgery outcomes.
To place this in context: in the Phase 2 trial published in the New England Journal of Medicine in 2023, approximately 16% of participants in the 8mg arm achieved ≥30% weight loss at 48 weeks, with the plateau of weight loss still underway at trial's end. The Phase 3 data, collected over longer durations and with a refined titration schedule, confirm that this level of response becomes accessible to a substantial proportion — not a small minority — of treated patients.
It is also worth noting that Phase 2 data showed ≥25% weight loss in 43–48% of participants at 48 weeks across the 8mg and 12mg arms. TRIUMPH-1 extends those observations meaningfully, with nearly half of the 12mg cohort crossing the 30% threshold by 80 weeks.
One question that follows naturally from any efficacy trial is whether the weight loss trajectory plateaus, reverses, or continues with extended treatment. According to Eli Lilly's announcement, individuals with a baseline BMI of 35 or higher who participated in a study extension continued to lose weight beyond the 80-week mark — suggesting that, at least in higher-BMI subgroups, the treatment effect had not yet reached its ceiling by the end of the primary trial period.
This is a clinically meaningful signal. Phase 2 data published in the NEJM showed that at 48 weeks, the weight loss curves for the 8mg and 12mg doses had not fully plateaued, implying that longer treatment durations would likely yield additional benefit. The TRIUMPH-1 extension data appear to confirm that hypothesis in a Phase 3 population.
It should be noted that TRIUMPH-1 Phase 3 results have been announced via Eli Lilly press release; peer-reviewed publication is pending as of April 2026, and retatrutide has not yet received FDA approval. An NDA filing has not been publicly confirmed at this time. As the full dataset undergoes peer review, additional clarity on subgroup effects, long-term safety, and durability of response will emerge.
Safety signals observed in TRIUMPH-4 remain relevant context: the most common adverse events were gastrointestinal in nature — nausea, diarrhea, and vomiting — consistent with the class effect seen across GLP-1-based therapies and replicated in Phase 2 data. Dysesthesia (abnormal skin sensations) was reported in 20.9% of the 12mg group in TRIUMPH-4, a rate meaningfully higher than placebo. Discontinuation rates in TRIUMPH-4 reached 18.2% in the 12mg arm, with some participants stopping due to perceived excessive weight loss — an unusual but documented phenomenon at this level of efficacy.
If the TRIUMPH-1 data hold up under peer review and regulatory scrutiny, retatrutide may represent the most effective pharmacological treatment for obesity ever evaluated in a large randomized controlled trial. The convergence of multiple Phase 3 datasets now points in the same direction: for patients with obesity, a once-weekly injection may soon be capable of delivering outcomes that were previously available only in an operating room.
Retatrutide is not yet FDA-approved, and no prescription or treatment can be promised or guaranteed at this time. For those who want to stay informed as the regulatory process advances, glp3md.com maintains a waitlist for individuals interested in receiving updates about retatrutide availability. Joining the waitlist is free, carries no commitment, and is intended solely to keep you informed — not to imply that medication will be available, prescribed, or dispensed at any particular time. As the science moves forward, being on the list means being among the first to know.
Join the waitlist for priority access to a prescribing physician when retatrutide receives FDA approval.
Join the WaitlistThis article is for educational purposes only and does not constitute medical advice. Retatrutide is an investigational drug and is not FDA approved as of publication. Clinical data referenced is from publicly available trial publications. Consult a qualified healthcare provider before making any treatment decisions.